Physician profile
Vikrant Salaria
NPI 1043211493
$6,742.90
in general payments reported to CMS, 2019-2025
35 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $1,031 · 2021: $1,356 · 2022: $340 · 2023: $676 · 2024: $962 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $934.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $919.75 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $641.74 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $597.93 | 2019-2025 | |
| Amgen INC. | $460.05 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $438.36 | 2021-2025 | Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $295.91 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $247.82 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.02 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $214.87 | 2019-2021 | |
| Mylan Specialty L.P. | $172.51 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $152.76 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.02 | 2019-2021 | |
| Abbott Laboratories | $138.17 | 2021-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $130.04 | 2019-2024 | Xyosted, Tlando, Nocdurna |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikrant Salaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.